Beneficial effects of soluble epoxide hydrolase inhibitors in myocardial infarction model

Insight gained using metabolomic approaches

Ning Li, Jun Yan Liu, Valeriy Timofeyev, Hong Qiu, Sung Hee Hwang, Dipika Tuteja, Ling Lu, Jun Yang, Hideki Mochida, Reginald Low, Bruce D. Hammock, Nipavan Chiamvimonvat

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Myocardial infarction (MI) leading to myocardial cell loss represents one of the common causes leading to cardiac failure. We have previously demonstrated the beneficial effects of several potent soluble epoxide hydrolase (sEH) inhibitors in cardiac hypertrophy. sEH catalizes the conversion of epoxyeicosatrienoic acids (EETs) to form the corresponding dihydroxyeicosatrienoic acids (DHETs). EETs are products of cytochrome P450 epoxygenases that have vasodilatory properties. Additionally, EETs inhibit the activation of nuclear factor (NF)-κB-mediated gene transcription. Motivated by the potential to uncover a new class of therapeutic agents for cardiovascular diseases which can be effectively used in clinical setting, we directly tested the biological effects of sEH inhibitors (sEHIs) on the progression of cardiac remodeling using a clinically relevant murine model of MI. We demonstrated that sEHIs were highly effective in the prevention of progressive cardiac remodeling post MI. Using metabolomic profiling of the inflammatory lipid mediators, we documented a significant decrease in EETs/DHETs ratio in MI model predicting a heightened inflammatory state. Treatment with sEHIs resulted in a change in the pattern of lipid mediators from one of inflammation towards resolution. Moreover, the oxylipin profiling showed a striking parallel to the changes in inflammatory cytokines in this model. Our study provides evidence for a possible new therapeutic strategy to improve cardiac function post MI.

Original languageEnglish (US)
Pages (from-to)835-845
Number of pages11
JournalJournal of Molecular and Cellular Cardiology
Volume47
Issue number6
DOIs
StatePublished - Dec 2009

Fingerprint

Epoxide Hydrolases
Metabolomics
Myocardial Infarction
Oxylipins
Lipids
Inflammation Mediators
Acids
Cardiomegaly
Cytochrome P-450 Enzyme System
Cardiovascular Diseases
Heart Failure
Cytokines
Therapeutics
Genes

Keywords

  • Epoxyeicosatrienoic acids
  • Myocardial infarction
  • Oxylipin profiling
  • Soluble epoxide hydrolase
  • Soluble epoxide hydrolase inhibitors

ASJC Scopus subject areas

  • Molecular Biology
  • Cardiology and Cardiovascular Medicine

Cite this

Beneficial effects of soluble epoxide hydrolase inhibitors in myocardial infarction model : Insight gained using metabolomic approaches. / Li, Ning; Liu, Jun Yan; Timofeyev, Valeriy; Qiu, Hong; Hwang, Sung Hee; Tuteja, Dipika; Lu, Ling; Yang, Jun; Mochida, Hideki; Low, Reginald; Hammock, Bruce D.; Chiamvimonvat, Nipavan.

In: Journal of Molecular and Cellular Cardiology, Vol. 47, No. 6, 12.2009, p. 835-845.

Research output: Contribution to journalArticle

Li, Ning ; Liu, Jun Yan ; Timofeyev, Valeriy ; Qiu, Hong ; Hwang, Sung Hee ; Tuteja, Dipika ; Lu, Ling ; Yang, Jun ; Mochida, Hideki ; Low, Reginald ; Hammock, Bruce D. ; Chiamvimonvat, Nipavan. / Beneficial effects of soluble epoxide hydrolase inhibitors in myocardial infarction model : Insight gained using metabolomic approaches. In: Journal of Molecular and Cellular Cardiology. 2009 ; Vol. 47, No. 6. pp. 835-845.
@article{1cdd17c60626458aa43609b520a9e9e6,
title = "Beneficial effects of soluble epoxide hydrolase inhibitors in myocardial infarction model: Insight gained using metabolomic approaches",
abstract = "Myocardial infarction (MI) leading to myocardial cell loss represents one of the common causes leading to cardiac failure. We have previously demonstrated the beneficial effects of several potent soluble epoxide hydrolase (sEH) inhibitors in cardiac hypertrophy. sEH catalizes the conversion of epoxyeicosatrienoic acids (EETs) to form the corresponding dihydroxyeicosatrienoic acids (DHETs). EETs are products of cytochrome P450 epoxygenases that have vasodilatory properties. Additionally, EETs inhibit the activation of nuclear factor (NF)-κB-mediated gene transcription. Motivated by the potential to uncover a new class of therapeutic agents for cardiovascular diseases which can be effectively used in clinical setting, we directly tested the biological effects of sEH inhibitors (sEHIs) on the progression of cardiac remodeling using a clinically relevant murine model of MI. We demonstrated that sEHIs were highly effective in the prevention of progressive cardiac remodeling post MI. Using metabolomic profiling of the inflammatory lipid mediators, we documented a significant decrease in EETs/DHETs ratio in MI model predicting a heightened inflammatory state. Treatment with sEHIs resulted in a change in the pattern of lipid mediators from one of inflammation towards resolution. Moreover, the oxylipin profiling showed a striking parallel to the changes in inflammatory cytokines in this model. Our study provides evidence for a possible new therapeutic strategy to improve cardiac function post MI.",
keywords = "Epoxyeicosatrienoic acids, Myocardial infarction, Oxylipin profiling, Soluble epoxide hydrolase, Soluble epoxide hydrolase inhibitors",
author = "Ning Li and Liu, {Jun Yan} and Valeriy Timofeyev and Hong Qiu and Hwang, {Sung Hee} and Dipika Tuteja and Ling Lu and Jun Yang and Hideki Mochida and Reginald Low and Hammock, {Bruce D.} and Nipavan Chiamvimonvat",
year = "2009",
month = "12",
doi = "10.1016/j.yjmcc.2009.08.017",
language = "English (US)",
volume = "47",
pages = "835--845",
journal = "Journal of Molecular and Cellular Cardiology",
issn = "0022-2828",
publisher = "Academic Press Inc.",
number = "6",

}

TY - JOUR

T1 - Beneficial effects of soluble epoxide hydrolase inhibitors in myocardial infarction model

T2 - Insight gained using metabolomic approaches

AU - Li, Ning

AU - Liu, Jun Yan

AU - Timofeyev, Valeriy

AU - Qiu, Hong

AU - Hwang, Sung Hee

AU - Tuteja, Dipika

AU - Lu, Ling

AU - Yang, Jun

AU - Mochida, Hideki

AU - Low, Reginald

AU - Hammock, Bruce D.

AU - Chiamvimonvat, Nipavan

PY - 2009/12

Y1 - 2009/12

N2 - Myocardial infarction (MI) leading to myocardial cell loss represents one of the common causes leading to cardiac failure. We have previously demonstrated the beneficial effects of several potent soluble epoxide hydrolase (sEH) inhibitors in cardiac hypertrophy. sEH catalizes the conversion of epoxyeicosatrienoic acids (EETs) to form the corresponding dihydroxyeicosatrienoic acids (DHETs). EETs are products of cytochrome P450 epoxygenases that have vasodilatory properties. Additionally, EETs inhibit the activation of nuclear factor (NF)-κB-mediated gene transcription. Motivated by the potential to uncover a new class of therapeutic agents for cardiovascular diseases which can be effectively used in clinical setting, we directly tested the biological effects of sEH inhibitors (sEHIs) on the progression of cardiac remodeling using a clinically relevant murine model of MI. We demonstrated that sEHIs were highly effective in the prevention of progressive cardiac remodeling post MI. Using metabolomic profiling of the inflammatory lipid mediators, we documented a significant decrease in EETs/DHETs ratio in MI model predicting a heightened inflammatory state. Treatment with sEHIs resulted in a change in the pattern of lipid mediators from one of inflammation towards resolution. Moreover, the oxylipin profiling showed a striking parallel to the changes in inflammatory cytokines in this model. Our study provides evidence for a possible new therapeutic strategy to improve cardiac function post MI.

AB - Myocardial infarction (MI) leading to myocardial cell loss represents one of the common causes leading to cardiac failure. We have previously demonstrated the beneficial effects of several potent soluble epoxide hydrolase (sEH) inhibitors in cardiac hypertrophy. sEH catalizes the conversion of epoxyeicosatrienoic acids (EETs) to form the corresponding dihydroxyeicosatrienoic acids (DHETs). EETs are products of cytochrome P450 epoxygenases that have vasodilatory properties. Additionally, EETs inhibit the activation of nuclear factor (NF)-κB-mediated gene transcription. Motivated by the potential to uncover a new class of therapeutic agents for cardiovascular diseases which can be effectively used in clinical setting, we directly tested the biological effects of sEH inhibitors (sEHIs) on the progression of cardiac remodeling using a clinically relevant murine model of MI. We demonstrated that sEHIs were highly effective in the prevention of progressive cardiac remodeling post MI. Using metabolomic profiling of the inflammatory lipid mediators, we documented a significant decrease in EETs/DHETs ratio in MI model predicting a heightened inflammatory state. Treatment with sEHIs resulted in a change in the pattern of lipid mediators from one of inflammation towards resolution. Moreover, the oxylipin profiling showed a striking parallel to the changes in inflammatory cytokines in this model. Our study provides evidence for a possible new therapeutic strategy to improve cardiac function post MI.

KW - Epoxyeicosatrienoic acids

KW - Myocardial infarction

KW - Oxylipin profiling

KW - Soluble epoxide hydrolase

KW - Soluble epoxide hydrolase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=70350604449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350604449&partnerID=8YFLogxK

U2 - 10.1016/j.yjmcc.2009.08.017

DO - 10.1016/j.yjmcc.2009.08.017

M3 - Article

VL - 47

SP - 835

EP - 845

JO - Journal of Molecular and Cellular Cardiology

JF - Journal of Molecular and Cellular Cardiology

SN - 0022-2828

IS - 6

ER -